CA
NZ
UK
AU
IND
US
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) develops oral, non-statin medicines for cardiovascular risk. SPINOZA is randomized, double-blind and placebo-controlled, and it enrolls adults with biomarker evidence suggestive of preclinical Alzheimer's who have no noticeable memory or functional symptoms. CEO Michael Davidson called the first dosing …
Sagimet Biosciences Inc. (NASDAQ:SGMT) is selling all securities itself. The 8,750,010 shares and 2,750,010 pre-funded warrants total about 11.5 million shares, which at USD 10 equals the USD 115.0 million raise. Pre-funded warrants are exercisable immediately for USD 0.0001, which lets large holders stay …
Moderna, Inc. (NASDAQ:MRNA) shares traded near USD 62 on August 18 and reached an intraday high of USD 208 on September 25. The rally followed news that the company and Merck (NYSE:MRK) reported that the personalized cancer vaccine intismeran autogene, combined with Keytruda, met …
Wednesday's session brought a sharp rebound for Capricor Therapeutics, Inc. (NASDAQ: CAPR), the Duchenne muscular dystrophy (DMD) cell-therapy developer. The stock gapped about 17% higher at the open after late-Tuesday 24-month data from the pivotal Phase 3 HOPE-3 trial and an analyst upgrade, and …
Wednesday's session delivered a sharp relief bounce for Inventiva S.A. (NASDAQ: IVA), the French clinical-stage biotech developing lanifibranor for MASH. After a three-week slide of nearly 40%, the stock opened above Tuesday's close and climbed 8.7% to $3.58 on heavy volume. Buyers pushed price …
Wednesday's session delivered a vertical breakout for Pacific Biosciences of California, Inc. (NASDAQ: PACB). The genomics-tools stock cleared a months-long ceiling near $1.80-$1.84 in one candle and closed at $2.42, its highest level since the January double top. Shares jumped sharply in the afternoon …
NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS) announced on September 29, 2026 that the first participant has been dosed in SPINOZA, a Phase 2b trial of its oral cholesterol drug candidate obicetrapib in people with preclinical Alzheimer's disease. The company furnished the announcement in a Form …
OneMedNet Corporation (NASDAQ:ONMD) reported in a Form 8-K filed on September 29, 2026 that a 1-for-10 reverse stock split of its common stock became effective at 12:01 a.m. Eastern Time on September 29, 2026. Stockholders had approved the action on September 18, 2026.
Quantum-Si Incorporated (NASDAQ:QSI) used a Form 8-K to put its next-generation protein sequencing platform, Proteus, in front of investors. The company furnished the slides it presented at World HUPO 2026 in Singapore, along with a press release, stating that the Proteus nanowell array has …
Silexion Therapeutics Corp (NASDAQ:SLXN) reported in a Form 8-K that on September 28, 2026 it entered into an inducement agreement with holders of 3,216,928 of its Series E warrants, who agreed to exercise them for cash at a reduced price of $0.2603 per share. …
Please wait processing your request...